Research programme: cell-cell fusion inhibiting peptides - Aplagen
Latest Information Update: 18 Mar 2011
At a glance
- Originator AplaGen
- Class Peptides
- Mechanism of Action Cell adhesion molecule inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 30 Jan 2007 Preclinical trials in Multiple sclerosis in Germany (Parenteral)